HPV vaccine study for women in Kambia
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests whether a single dose of the HPV vaccine (Gardasil 9) can reduce HPV infection and transmission in women. It might help prevent cervical cancer and other HPV-related conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born female and are between 18 and 29 years old.
- You live in the Kambia district or nearby and plan to stay for the next 12 months.
- You are in good health and are not HIV positive.
- You are not pregnant, and if you are sexually active, you agree to use birth control during the study.
- You have not had an HPV vaccine before.
- You are willing to provide samples (cervical, urine, blood) and possibly receive one dose of the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
This trial tests a way to give HPV vaccines along with routine childhood immunizations in Ghana. It aims to protect against HPV, a virus that can cause cervical cancer, by making it easier to get the vaccine.
This study looks at how well the HPV vaccine works in women who have already been exposed to the virus through sexual activity. It aims to understand the immune response and potentially improve protection against HPV-related cancers.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.